Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.
Anna SundlövKatarina Sjögreen-GleisnerJohanna SvenssonMichael LjungbergTomas OlssonPeter BernhardtJan TennvallPublished in: European journal of nuclear medicine and molecular imaging (2017)
Individualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.